Jupiter Neurosciences, Inc.
JUNS
$5.24
-$0.76-12.67%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -10.99% | -76.17% | 788.68% | 651.14% | 372.85% |
| Gross Profit | 14.98% | 87.01% | -788.68% | -651.14% | -372.85% |
| SG&A Expenses | 46.20% | 121.31% | 268.63% | 230.13% | 126.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.85% | 94.09% | 365.47% | 306.55% | 169.49% |
| Operating Income | -27.63% | -92.59% | -365.47% | -306.55% | -169.49% |
| Income Before Tax | -34.87% | -68.57% | -287.14% | -819.58% | -141.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.87% | -68.57% | -287.14% | -819.58% | -141.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.87% | -68.57% | -287.14% | -819.58% | -141.11% |
| EBIT | -27.63% | -92.59% | -365.47% | -306.55% | -169.49% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -26.62% | -39.54% | -253.68% | -695.61% | -93.31% |
| Normalized Basic EPS | -26.64% | -65.37% | -252.94% | -192.41% | -81.76% |
| EPS Diluted | -26.62% | -40.37% | -253.68% | -800.00% | -93.31% |
| Normalized Diluted EPS | -26.64% | -65.37% | -252.94% | -226.15% | -81.76% |
| Average Basic Shares Outstanding | 6.50% | 20.66% | 9.57% | 20.50% | 24.80% |
| Average Diluted Shares Outstanding | 6.50% | 20.66% | 9.57% | 8.46% | 24.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |